Sign in

The Lancet Rheumatology

@thelancetrheum.bsky.social
1.1K followers 244 following 218 posts

The #LancetRheumatology is a clinical #rheumatology journal publishing innovative & practice-changing research & opinion across all #rheumatic & #MSK disorders. 🌐 www.thelancet.com/journals/lanrhe/h…

PostsRepliesMedia
The Lancet Rheumatology @thelancetrheum.bsky.social · 10h
Read the update in full here ➡️bit.ly/4rMqjLy
bit.ly
CAR T cells for autoimmune diseases: 2026 update of the EBMT–ISCT–JACIE practice harmonisation and consensus recommendations
Autoimmune diseases are a heterogeneous group of chronic diseases characterised by loss of immune tolerance with substantial morbidity and mortality. Since 2021, chimeric antigen receptor (CAR) T cell...
023
The Lancet Rheumatology @thelancetrheum.bsky.social · 10h
NEW—CAR T cells for autoimmune diseases: 2026 update of the EBMT–ISCT–JACIE practice harmonisation and consensus recommendations bit.ly/4rMqjLy #MedSky #RheumSky #NeuroSky #HaemSky
001
The Lancet Rheumatology @thelancetrheum.bsky.social · 02/10/2026
NEW in @thelancet.com—Physiotherapist-led care for musculoskeletal conditions in the emergency department (RESHAP-ED): a randomised controlled trial with economic evaluation www.thelancet.com/journals/lan... #MedSky #RheumSky #PhysioSky
122
The Lancet Rheumatology @thelancetrheum.bsky.social · 29/09/2026
NEW RESEARCH—Predicting prevalence and severity of cytokine release syndrome after CAR T-cell therapy in patients with autoimmune disease: a retrospective cohort study bit.ly/4hujPwa Plus, linked Comment bit.ly/4hrWLy8 #MedSky #RheumSky
Incidence of cytokine release syndrome after autologous CAR T-cell therapy by baseline biomarker. Concentrations are log scales. Dots indicate individual patients and error bars indicate 95% CIs.
011
The Lancet Rheumatology @thelancetrheum.bsky.social · 25/09/2026
NEW RESEARCH—Minimal residual disease flow cytometry of peripheral blood B-cell subsets in patients with idiopathic inflammatory myopathies following rituximab therapy: a single-centre, retrospective cohort study thelancet.com/journals/lan... #MedSky #RheumSky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 25/09/2026
NEW RESEARCH—Minimal residual disease flow cytometry of peripheral blood B-cell subsets in patients with idiopathic inflammatory myopathies following rituximab therapy: a single-centre, retrospective cohort study www.thelancet.com/journals/lan... #MedSky #RheumSky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 23/09/2026
Our Oct 2026 issue is live! Including research on #musculoskeletal #ultrasound and #lupus #arthritis, plus much more! thelancet.com/journals/lan... Cover by @emma-cheng.bsky.social #Medsky #Rheumsky
002
The Lancet Rheumatology @thelancetrheum.bsky.social · 17/09/2026
NEW RESEARCH—Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial www.thelancet.com/journals/lan... #MedSky #RheumSky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 16/09/2026
NEW COMMENT—Beyond vasomotor symptoms: reframing musculoskeletal health in the Women's Health Strategy www.thelancet.com/journals/lan... #MedSky #RheumSky #WomensHealthSky
Proposed integration of women’s health hubs and musculoskeletal services
010
The Lancet Rheumatology @thelancetrheum.bsky.social · 11/09/2026
NEW PERSONAL VIEW—Prehabilitation in rheumatology: a missing link in psoriatic disease management www.thelancet.com/journals/lan... #MedSky #RheumSky @stefansiebert.bsky.social
Domains of prehabilitation in psoriatic disease. Mechanistic pathways and expected outcomes are extrapolated from evidence in perioperative and chronic disease settings and adapted to psoriatic disease
110
The Lancet Rheumatology @thelancetrheum.bsky.social · 04/09/2026
NEW RESEARCH—Derivation, validation, and proposed thresholds of the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) instrument: a cohort study www.thelancet.com/journals/lan... #MedSky #RheumSky
010
Reposted by The Lancet Rheumatology
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 27/08/2026
📢 We’ve published our first issue! Read and download our inaugural issue here ➡️ www.thelancet.com/issue/S3117-... Thank you to our authors and reviewers for their valuable contributions ✨ As a gold open access journal, our content is free to read by everyone, always. #OA #MedSky #RadSky
Image ALT text: Representative images of individuals with different NMN BBB scores. The left column shows contrast enhanced MRI brain scans and the right column shows the fusion of the MRI scans and PET scans of these same individuals.  The top row corresponds to an individual with a NMN BBB score of 2 as minor parts of PET-positive volume show contrast enhancement on MRI. The bottom row corresponds to an individual with a NMN BBB score of 5 as the PET positive volume shows complete contrast enhancement on MRI. 
Copyright: The authors, Nathalie Albert and colleagues. Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
178
The Lancet Rheumatology @thelancetrheum.bsky.social · 27/08/2026
NEW—ERN ReCONNET–SLICC–SLEuro consensus on the therapeutic management of rare systemic lupus erythematosus manifestations (part 2) Free to read with registration on lancet.com (also free): www.thelancet.com/journals/lan... #Medsky #Rheumsky
010
The Lancet Rheumatology @thelancetrheum.bsky.social · 18/08/2026
Our Sept 2026 issue is live! Including research on #BMI and JAK inhibtors, predicting #psoriaticarthritis, rheumatic disease diagnoses pre and post #COVID19, and a #secukinumab #biosimilar, plus much more! www.thelancet.com/journals/lan... Cover by @emma-cheng.bsky.social #Medsky #Rheumsky
120
The Lancet Rheumatology @thelancetrheum.bsky.social · 14/08/2026
NEW RESEARCH—Impact of #BMI on response to Janus kinase inhibitors in rheumatoid #arthritis: an individual patient data meta-analysis of randomised controlled trials bit.ly/4x3qiEW Plus linked Comment bit.ly/4zmBdv6 #Medsky #Rheumsky
Adjusted predicted outcomes by BMI category in participants receiving JAK inhibitors or placebo
010
Reposted by The Lancet Rheumatology
The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 06/08/2026
🎉Our 10th anniversary issue is out now, featuring a collection of Comments looking back over the past decade in key areas of gastroenterology & hepatology + our usual range of content covering topics incl #IBD, #LynchSyndrome, #MASH + more! www.thelancet.com/gastrohep #GastroSky #MedSky #LiverSky
053
The Lancet Rheumatology @thelancetrheum.bsky.social · 06/08/2026
NEW RESEARCH—Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine study bit.ly/4whjqCF Plus, linked Comment bit.ly/4bzCKUb #Medsky #Rheumsky
IFNα and oligoprotein IFN signatures in Sjögren’s disease
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 30/07/2026
NEW REVIEW—When and how chronicity develops in rheumatoid arthritis: towards a temporal and tissue-integrated perspective www.thelancet.com/journals/lan... @alpercvrgl.bsky.social #Medsky #Rheumsky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 21/07/2026
Our August 2026 issue is live! Including research on sacroiliac joint #bonemarrowoedema, a precision medicine tool in #Sjögrens disease, the role of #healthliteracy in #inflammatoryarthritis, plus much more! thelancet.com/journals/lanrhe/home Cover by @emma-cheng.bsky.social #Medsky #Rheumsky
065
The Lancet Rheumatology @thelancetrheum.bsky.social · 17/07/2026
NEW RESEARCH—Predicting psoriatic arthritis in new-onset psoriasis: development of multivariable prediction models from an inception cohort study bit.ly/4fjXEHN And linked Comment bit.ly/4fqXkr7 #Medsky #Rheumsky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 11/07/2026
NEW EDITORIAL—The end for avacopan In our August editorial we discuss the ongoing controversy surrounding avacopan that could spell the end for the drug www.thelancet.com/journals/lan... #Medsky #Rheumsky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 09/07/2026
NEW RESEARCH—5-year data from the TREAT EARLIER trial shows that a time-limited methotrexate intervention has different effects in patients with ACPA-positive and ACPA-negative arthralgia at increased risk for rheumatoid arthritis www.thelancet.com/journals/lan... #Medsky #Rheumsky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 07/07/2026
NEW RESEARCH—Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase 3 trial www.thelancet.com/journals/lan... #Medsky #Rheumsky #Dermsky
Percentage change from baseline in Psoriasis Area Severity Index scores in treatment period one
010
The Lancet Rheumatology @thelancetrheum.bsky.social · 03/07/2026
NEW RESEARCH—Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using @OpenSAFELY bit.ly/4p6WELY Plus linked Comment by @jeffsparks.bsky.social bit.ly/446onmh
Comparison between observed and expected diagnosis rates of autoimmune rheumatic diseases in England after the onset of the COVID-19 pandemic
012
The Lancet Rheumatology @thelancetrheum.bsky.social · 01/07/2026
We are a world-leading #rheumatology journal, ranking:   #2 Journal Impact Factor (29·5)   #3 Scopus CiteScore (28·5)  Explore our high impact and global reach: hubs.li/Q04k_q2n0 #RheumSky
hubs.li
About The Lancet Rheumatology
100
Reposted by The Lancet Rheumatology
The Lancet @thelancet.com · 01/07/2026
🥇 The Lancet is now ranked the world’s #1 general medical journal—in both Journal Impact Factor (109·0) and Scopus CiteScore (92·4). No other general medical journal comes close. Your next clinical breakthrough belongs here. Learn more ➡️ hubs.ly/Q04k-V2N0
The Lancet promotional graphic: 'No other general medical journal comes close.' Highlighting a Journal Impact Factor of 109·0 (Clarivate 2026) and Scopus CiteScore of 92·4. Copyright: Elsevier Ltd.
1101
The Lancet Rheumatology @thelancetrheum.bsky.social · 25/06/2026
NEW HEALTH POLICY—Aligning approaches to rheumatoid arthritis drug development: a comparison of FDA and EMA guidance www.thelancet.com/journals/lan... #Medsky #Rheumsky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 23/06/2026
Our July 2026 issue is live! Including clinical trials in cutaneous #lupus, #Sjogrens disease, and #RheumatoidArthritis, plus much more! thelancet.com/journals/lan... Cover by @emma-cheng.bsky.social #Medsky #Rheumsky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 19/06/2026
NEW Patient Voice—Beyond laboratory tests: when normal results aren’t the finish line—by Dana Guglielmo www.thelancet.com/journals/lan... #Medsky #Rheumsky
010
The Lancet Rheumatology @thelancetrheum.bsky.social · 15/06/2026
NEW COMMENT—Baricitinib and ruxolitinib use through the UK #HLH Network www.thelancet.com/journals/lan... #Medsky #Rheumsky #IDsky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 03/06/2026
📢Announcing @thelancetrheum.bsky.social Commission on reproductive health and family planning in immune-mediated long-term conditions: empowering special reproductive journeys Read all about it here ➡️https://bit.ly/4vrdHKt @lauraandreoli.bsky.social @karenschreiber.bsky.social
Addressing the continuum of reproductive health care and family planning for people with immune-mediated long-term conditions from individual to policy makers and regulatory bodies
151
Reposted by The Lancet Rheumatology
Bethan Goulden @bethangoulden.bsky.social · 02/06/2026
🥇 The first @thelancetrheum.bsky.social commission was born today! 🎯 Our vision: A future where people living with immune mediated long term conditions achieve sexual & reproductive wellbeing across their life course. @lauraandreoli.bsky.social @karenschreiber.bsky.social #LancetRheumCommission
082
The Lancet Rheumatology @thelancetrheum.bsky.social · 01/06/2026
NEW RESEARCH—The role of health literacy in clinical, treatment, and work-related outcomes in people with inflammatory #arthritis in England: a cross-sectional study bit.ly/4vntQk9 @drminidey.bsky.social And linked Comment bit.ly/4a6amrX #Medsky #Rheumsky
010
The Lancet Rheumatology @thelancetrheum.bsky.social · 28/05/2026
Attending #EULAR2026 in London next week? Anna Clark, Editor-in-Chief, invites you to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BLchR0 #Medsky #Rheumsky
010
The Lancet Rheumatology @thelancetrheum.bsky.social · 27/05/2026
Our June 2026 issue is live! Including research on genetics of #SystemicSclerosis, clinical criteria for #Still's disease, difficult-to-treat #RheumatoidArthritis, and time to #pregnancy in RA, plus much more! www.thelancet.com/journals/lan... Cover by @emma-cheng.bsky.social #Medsky #Rheumsky
020
The Lancet Rheumatology @thelancetrheum.bsky.social · 26/05/2026
NEW—Long-term treatment transition patterns after intensive treatment strategies in early psoriatic arthritis: insights from the GOLMePsA clinical trial www.thelancet.com/journals/lan... #Medsky #Rheumsky
010
The Lancet Rheumatology @thelancetrheum.bsky.social · 22/05/2026
NEW RESEARCH—Prevalence and determinants of sacroiliac joint bone marrow oedema in the general population in Germany: a population-based cross-sectional study www.thelancet.com/journals/lan... #Medsky #Rheumsky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 19/05/2026
NEW VIEWPOINT—When one joint matters: the monoarticular blind spot in inflammatory arthritis www.thelancet.com/journals/lan... #Medsky #Rheumsky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 08/05/2026
NEW RESEARCH—Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a phase 2 trial bit.ly/42WYW5O Linked Comment bit.ly/4314gVL #WorldLupusDay #Rheumsky
121
The Lancet Rheumatology @thelancetrheum.bsky.social · 06/05/2026
NEW podcast episode 🎧 Acting Deputy Editor, Aisling O'Brien, talks to Dirk Foell about trends in paediatric rheumatology care across Europe Listen now wherever you get your podcasts! Apple: bit.ly/4tkAqXf Spotify: bit.ly/4ncXWUF Full Viewpoint: bit.ly/4eqGxp6 #Medsky #Rheumsky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 01/05/2026
NEW RESEARCH—Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study bit.ly/49mVODT #Medsky #Rheumsky
010
The Lancet Rheumatology @thelancetrheum.bsky.social · 24/04/2026
NEW RESEARCH—Sex-specific autosomal susceptibility loci in systemic sclerosis: a genome-wide association study bit.ly/3OHY4ys Plus, linked Comment bit.ly/4e8AvJK #Medsky #Rheumsky
152
The Lancet Rheumatology @thelancetrheum.bsky.social · 22/04/2026
Our May 2026 issue is live! Including research on #hyperuricaemia, #gout, zoster #vaccine, and #JIA, plus much more! www.thelancet.com/journals/lan... Cover by @emma-cheng.bsky.social #Medsky #Rheumsky
011
The Lancet Rheumatology @thelancetrheum.bsky.social · 20/04/2026
NEW RESEARCH—Associated lifestyle factors and comorbidities of difficult-to-treat rheumatoid arthritis: a systematic review and meta-analysis bit.ly/4tSOebX Plus linked Comment bit.ly/4cFTGIr #Medsky #Rheumsky
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 15/04/2026
NEW—Detection of GLP-1 and DPP-4 in synovial fluid: implications for therapeutical strategies in arthritis bit.ly/4my0EUf #MedSky #RheumSky
(A) Soluble GLP-1 concentrations in plasma and synovial fluid in patients with rheumatoid arthritis (n=22), spondyloarthritis (n=22), and in plasma in healthy controls (n=29). (B) Soluble DPP-4 activity in plasma and synovial fluid in patients with rheumatoid arthritis (n=12), spondyloarthritis (n=18), and in plasma in healthy controls (n=7).
082
The Lancet Rheumatology @thelancetrheum.bsky.social · 08/04/2026
NEW REVIEW—Glucocorticoid treatment in patients with inflammatory rheumatic diseases: current practice and open questions bit.ly/3PP9xwD
Mechanism of glucocorticoid actions
000
The Lancet Rheumatology @thelancetrheum.bsky.social · 30/03/2026
NEW podcast episode 🎧 As part of our theme issue on patient and public involvement in rheumatology, Aisling O'Brien talks to Jon Lampa about patient-reported outcomes from the NORD-STAR trial Listen on Apple bit.ly/4rYkOYD Spotify bit.ly/4cdG4oB Full Article bit.ly/411D48I #Medsky #Rheumsky
000
Reposted by The Lancet Rheumatology
Lupus Europe @lupuseurope.bsky.social · 26/03/2026
💥 KABOOM! Our #LupusGPT work is now published in @thelancetrheum.bsky.social‼️ 🏆 A big moment for LupusGPT, but also for what can happen when patient voice is built in from the start, not added at the end. Free. Multilingual. Valid information on lupus doi.org/10.1016/S266...
121
The Lancet Rheumatology @thelancetrheum.bsky.social · 26/03/2026
NEW RESEARCH—Development and validation of clinical criteria for the definition of disease activity in adult-onset Still's disease: a cohort study bit.ly/4rZwyKH Plus, linked Comment bit.ly/4dgPYHf #Medsky #Rheumsky
 Correlation between clinical variables and disease activity
010
Reposted by The Lancet Rheumatology
Karolinska Institutet @ki.se · 24/03/2026
Early treatment for #RheumatoidArthritis leads to significant improvements in pain, fatigue, and quality of life – regardless of whether patients receive biologic drugs or conventional therapy. New KI study published in @thelancetrheum.bsky.social 🧪 #Rheumatology news.ki.se/early-initia...
news.ki.se
Early initiation of treatment alleviates symptoms in rheumatism
Early treatment for rheumatoid arthritis leads to significant improvements in pain, fatigue, and quality of life — regardless of whether patients receive biologic drugs or conventional therapy. This i...
142